nei THIS MONTH IN
PSYCHOPHARMACOLOGY
Browsing articles in "Pain"

 

FDA Approves Ubrogepant for Acute Treatment of Migraine
January 24, 2020   

Schizophrenia is a lifelong illness affecting approximately 2.4 milliMigraine, an episodic neurologic condition encompassing headaches, sensitivity to light and sounds, and nausea, affects over 30 million individuals in the United States and is the 2nd leading cause of disability worldwide. Fortunately...
 Continue reading (Members only)
FDA Does Not Approve Sublingual Buprenorphine Spray for Pain
August 13, 2018   

The FDA has opted not to approve a new formulation of the opioid medication...
 Continue reading (Members only)
Can Cannabis Use Reduce Opioid Use?
February 9, 2018   

Given the ongoing prescription opioid use disorder epidemic as well as the increasing legalization and availability of marijuana, the authors sought to determine whether marijuana use reduced the non-medical use of prescribed opioids...
 Continue reading
Increased Risk of Opioid-Related Death in Patients Taking Concomitant Gabapentin
October 16, 2017   

A new study examined the increased risk for opioid-related death in patients taking concomitant prescription opioids and gabapentin...
 Continue reading (Members only)
Highlights from the 2017 APA Annual Meeting
June 8, 2017   

The 2017 APA annual meeting, held in NEI's hometown of San Diego, was themed "Prevention Through Partnership" and included more than 400 sessions. Here, we provide highlights of the meeting, including NEI's podcast interviews with expert presenters, key research from the poster sessions, and NEI's debut live concert--the NEI PsychopharmaJam.
 Continue reading
Report on Health Effects of Cannabis Released by National Academies of Sciences, Engineering, and Medicine
February 3, 2017   

With the recent legalization of both medical and recreational use in numerous states across the nation (and an estimated 22 million cannabis users in the United States), there is growing interest regarding the potential benefits and risks associated with marijuana use. It is therefore apropos that the Committee on the Health Effects of Marijuana (as part of the National Academies of Sciences, Engineering, and Medicine) has published a report that reviews the state of existing evidence on both the positive and negative effects of marijuana as well as recommendations for future research...
 Continue reading (Members only)
Increase in Opioid-Related Deaths Not Driven By Prescription Painkillers
January 12, 2017   

Opioid abuse remains an epidemic in the United States, with over 50,000 deaths associated with drug overdose, and 63% of those attributed to opioids...
 Continue reading (Members only)
Oral Ketamine Relieves Depression in Patients with Chronic Pain
November 17, 2016   

In a six-week randomized, double-blind study, 150 mg of oral ketamine was compared to 150 mg of diclofenac, administered daily to patients with chronic pain...
 Continue reading (Members only)
FDA Alert: Medication and Medical Device Approvals
September 12, 2016   

The US FDA has approved the marketing of computerized cognitive tests to assess for possible concussions, granted tentative approval for Trokendi XR for migraine prevention, and approved abuse-deterrent Troxyca ER for severe pain management.
 Continue reading (Members only)
FDA Alert: Boxed Warning for Combined Use of Opioids and Benzodiazepines
September 2, 2016   

The US FDA is added a boxed warning to the labels of opioid pain and opioid cough medications and benzodiazepines regarding the increased risk of central nervous system (CNS) depressant effects when these medications are used together...
 Continue reading (Members only)
12
Top of Page